Deutsche Bank Aktiengesellschaft Raises Albemarle (NYSE:ALB) Price Target to $305.00

Albemarle (NYSE:ALBGet Rating) had its price target boosted by analysts at Deutsche Bank Aktiengesellschaft from $290.00 to $305.00 in a research note issued on Wednesday, The Fly reports. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential upside of 15.81% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Mizuho cut their price objective on Albemarle from $325.00 to $300.00 and set a “neutral” rating for the company in a research report on Thursday, January 12th. Robert W. Baird lifted their price objective on Albemarle from $298.00 to $305.00 in a research report on Wednesday. Vertical Research upgraded Albemarle from a “hold” rating to a “buy” rating and set a $275.00 price objective for the company in a research report on Wednesday, January 4th. StockNews.com started coverage on Albemarle in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Finally, Morgan Stanley boosted their target price on Albemarle from $145.00 to $155.00 and gave the stock an “underweight” rating in a research report on Monday, November 28th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $294.37.

Albemarle Price Performance

Shares of Albemarle stock traded down $1.22 during midday trading on Wednesday, hitting $263.37. 299,806 shares of the company were exchanged, compared to its average volume of 1,468,007. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.73 and a quick ratio of 1.08. The firm has a market cap of $30.85 billion, a P/E ratio of 19.97, a PEG ratio of 0.60 and a beta of 1.45. Albemarle has a 52 week low of $169.93 and a 52 week high of $334.55. The firm has a 50 day simple moving average of $248.26 and a 200-day simple moving average of $259.38.

Albemarle (NYSE:ALBGet Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The specialty chemicals company reported $7.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.84 by $0.66. Albemarle had a return on equity of 26.84% and a net margin of 27.77%. The firm had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the company posted $1.05 EPS. The business’s revenue for the quarter was up 151.9% compared to the same quarter last year. Research analysts forecast that Albemarle will post 20.95 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Scott Tozier sold 1,719 shares of Albemarle stock in a transaction on Friday, January 6th. The stock was sold at an average price of $220.00, for a total transaction of $378,180.00. Following the completion of the sale, the chief financial officer now directly owns 63,384 shares of the company’s stock, valued at $13,944,480. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Albemarle news, CFO Scott Tozier sold 1,719 shares of the business’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $220.00, for a total value of $378,180.00. Following the completion of the transaction, the chief financial officer now directly owns 63,384 shares of the company’s stock, valued at $13,944,480. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Karen G. Narwold sold 2,250 shares of the business’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $280.25, for a total value of $630,562.50. Following the completion of the transaction, the executive vice president now directly owns 6,257 shares of the company’s stock, valued at $1,753,524.25. The disclosure for this sale can be found here. Insiders sold a total of 17,681 shares of company stock valued at $5,310,662 over the last three months. Company insiders own 0.25% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SJS Investment Consulting Inc. bought a new stake in shares of Albemarle in the third quarter valued at about $28,000. Covestor Ltd lifted its holdings in shares of Albemarle by 51.2% in the first quarter. Covestor Ltd now owns 130 shares of the specialty chemicals company’s stock valued at $29,000 after purchasing an additional 44 shares in the last quarter. Tompkins Financial Corp lifted its holdings in shares of Albemarle by 50.0% in the fourth quarter. Tompkins Financial Corp now owns 150 shares of the specialty chemicals company’s stock valued at $33,000 after purchasing an additional 50 shares in the last quarter. Riverview Trust Co lifted its holdings in shares of Albemarle by 92.3% in the second quarter. Riverview Trust Co now owns 175 shares of the specialty chemicals company’s stock valued at $37,000 after purchasing an additional 84 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Albemarle in the third quarter valued at about $37,000. 82.24% of the stock is owned by institutional investors and hedge funds.

Albemarle Company Profile

(Get Rating)

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Lithium, Bromine, Catalysts, and All Other.

Read More

The Fly logo

Analyst Recommendations for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.